Skip to content
sellModerate cluster of 2

Cortney Caudill sold $2.0M of HALO

SVP, CHIEF OPERATING OFFICER at HALOZYME THERAPEUTICS, INC.. 28,857 shares at an average of $67.75, traded Mar 9, 2026, filed Mar 10, 2026.

Warning score
58
Value
$2.0M
28,857 shares
Holdings after
7,055
-84% from before
From 52-week low
+42%
low $47.91, close $68.14
From 52-week high
-16%
high $81.23, as of Mar 9, 2026

Score components

  • Role
    COO
    +20
  • Trade size
    $2.0M at market
    +25
  • Share of holdings sold
    Sold 84% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HALOOct 9, 2026 · close 110.42
Since filing Mar 10, 2026: +62.8%SPY +15.9% · excess +47.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001159036-26-000033, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 9, 2026MOption exercise
Common Stock
+20,000$33.51$670k34,366Mar 10, 2026
Mar 9, 2026SOpen-market sale
Common Stock
-17,900$67.75$1.2M16,466Mar 10, 2026
Mar 9, 2026SOpen-market sale
Common Stock
-2,100$68.25$143k14,366Mar 10, 2026
Mar 10, 2026MOption exercise
Common Stock
+1,546$33.51$52k15,912Mar 10, 2026
Mar 10, 2026SOpen-market sale
Common Stock
-8,857$67.64$599k7,055Mar 10, 2026
Mar 9, 2026MOption exercise
Option to Purchase Common Stockderivative
-20,000$33.51$670k69,224Mar 10, 2026
Mar 10, 2026MOption exercise
Option to Purchase Common Stockderivative
-1,546$33.51$52k67,678Mar 10, 2026

Related signals

Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$6.6M
60,000 shares
-8%
22Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$568k
5,230 shares
-9%
33Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$2.0M
18,996 shares
-24%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$6.4M
60,000 shares
-8%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$3.5M
50,000 shares
-6%
15Weak
HALOsell10b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$3.9M
50,000 shares
-7%
6Weak
HALOsell10b5-1
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton
director
$141k
2,000 shares
-5%
44Moderate
HALOsell 3
HALOZYME THERAPEUTICS, INC.
Cortney Caudill
SVP, CHIEF OPERATING OFFICER
$278k
4,263 shares
-25%
10Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton
director
$59k
829 shares
-2%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$1.1M
16,569 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Cortney Caudill sold $2.0M of HALO | InsiderTell